Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 34Uterine Cervical Neoplasms 24Fallopian Tube Neoplasms 18Endometrial Neoplasms 16Neoplasm Metastasis 10Lung Neoplasms 9Pancreatic Neoplasms 8Stomach Neoplasms 7Colorectal Neoplasms 7Carcinoma, Transitional Cell 7Breast Neoplasms 7Melanoma 6Carcinoma, Renal Cell 6Prostatic Neoplasms 5Esophageal Neoplasms 5Carcinosarcoma 5Carcinoma, Hepatocellular 5Vaginal Neoplasms 4Triple Negative Breast Neoplasms 4Thyroid Neoplasms 4Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Testicular Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Multiple Myeloma 3Cholangiocarcinoma 3Brain Neoplasms 3Vulvar Neoplasms 2

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × Magnetic Resonance Spectroscopy × Gynecologic × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡